The stock of Processa Pharmaceuticals Inc (PCSA) has seen a -12.41% decrease in the past week, with a -28.02% drop in the past month, and a -44.92% decrease in the past quarter. The volatility ratio for the week is 8.99%, and the volatility levels for the past 30 days are at 9.98% for PCSA. The simple moving average for the last 20 days is -17.29% for PCSA stock, with a simple moving average of -51.48% for the last 200 days.
Is It Worth Investing in Processa Pharmaceuticals Inc (NASDAQ: PCSA) Right Now?
Additionally, the 36-month beta value for PCSA is 0.57. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 1 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for PCSA is 3.33M and currently, short sellers hold a 3.59% ratio of that float. The average trading volume of PCSA on January 22, 2025 was 332.60K shares.
PCSA) stock’s latest price update
The stock price of Processa Pharmaceuticals Inc (NASDAQ: PCSA) has plunged by -10.02 when compared to previous closing price of 0.81, but the company has seen a -12.41% decline in its stock price over the last five trading sessions. globenewswire.com reported 2024-10-02 that HANOVER, Md., Oct. 02, 2024 (GLOBE NEWSWIRE) — Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (Processa or the Company), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs with improved efficacy and safety, today announced that the first patient has been dosed in a Phase 2 clinical trial evaluating NGC-Cap for the treatment of advanced or metastatic breast cancer.
Analysts’ Opinion of PCSA
Many brokerage firms have already submitted their reports for PCSA stocks, with H.C. Wainwright repeating the rating for PCSA by listing it as a “Buy.” The predicted price for PCSA in the upcoming period, according to H.C. Wainwright is $8 based on the research report published on April 25, 2024 of the previous year 2024.
PCSA Trading at -26.29% from the 50-Day Moving Average
After a stumble in the market that brought PCSA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -89.82% of loss for the given period.
Volatility was left at 9.98%, however, over the last 30 days, the volatility rate increased by 8.99%, as shares sank -22.87% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -33.91% lower at present.
During the last 5 trading sessions, PCSA fell by -12.41%, which changed the moving average for the period of 200-days by -69.19% in comparison to the 20-day moving average, which settled at $0.8789. In addition, Processa Pharmaceuticals Inc saw -17.74% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at PCSA starting from Young David, who purchase 21,000 shares at the price of $2.45 back on Feb 07 ’24. After this action, Young David now owns 79,387 shares of Processa Pharmaceuticals Inc, valued at $51,526 using the latest closing price.
Young David, the Pres. Research & Development of Processa Pharmaceuticals Inc, purchase 20,000 shares at $2.53 during a trade that took place back on Feb 06 ’24, which means that Young David is holding 58,387 shares at $50,504 based on the most recent closing price.
Stock Fundamentals for PCSA
The total capital return value is set at -3.92. Equity return is now at value -211.71, with -176.99 for asset returns.
Based on Processa Pharmaceuticals Inc (PCSA), the company’s capital structure generated 0.03 points at debt to capital in total, while cash flow to debt ratio is standing at -114.84. The debt to equity ratio resting at 0.03. The interest coverage ratio of the stock is -3.48.
Currently, EBITDA for the company is -11.46 million with net debt to EBITDA at 0.24. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.97.
Conclusion
In conclusion, Processa Pharmaceuticals Inc (PCSA) has seen bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
